What is already known about this topic? Currently, the 13-valent pneumococcal conjugate vaccine (PCV)
(PCV13) and the 23-valent pneumococcal polysaccharide
vaccine (PPSV23) are recommended for U.S. adults.
Recommendations vary by age and risk groups.
What is added by this report?
On October 20, 2021, the Advisory Committee on Immunization
Practices recommended 15-valent PCV (PCV15) or 20-valent
PCV (PCV20) for PCV–naïve adults who are either aged
≥65 years or aged 19–64 years with certain underlying conditions.
When PCV15 is used, it should be followed by a dose of
PPSV23, typically ≥1 year later.
What are the implications for public health practice?
Pneumococcal vaccination recommendations were simplified
across age and risk group. Eligible adults may receive either
PCV15 in series with PPSV23 or PCV20 alone.
To obtain and read the MMWR go to: Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 (cdc.gov)